Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
261-280 of 604 trials

Systemic Lupus Erythematosus: Obexelimab Study

We are studying a new medication, Obexelimab, for patients with systemic lupus erythematosus to see if it can lower disease activity and reduce fatigue. This trial compares its effects to a placebo treatment.

Systemic Lupus Erythematosus6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Intranasal COVID-19 Vaccine: LVT-001

We are studying a new intranasal booster vaccine for COVID-19 to see if it is safe and more effective than the standard mRNA vaccine. This trial is for healthy adults who want to help improve COVID-19 vaccination strategies.

COVID-191-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInfectious Diseases

Kidney Transplant Rejection: INTERCEPT Study

We are studying whether adding TCZ to standard treatment helps kidney transplant recipients with chronic rejection maintain better kidney function. The trial also looks at the safety of this treatment and its effects on overall health.

Chronic Active Antibody-Mediated Rejection>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Glioma Treatment Study: Temozolomide and Lomustine

We are testing a combination of chemotherapy and radiotherapy for patients with newly diagnosed grade 2 or 3 glioma. The goal is to see if this approach improves survival compared to standard treatments.

Newly Diagnosed Glioma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Advanced Solid Tumors: BT5528 Treatment Study

We are testing a new drug, BT5528, for patients with advanced solid tumors that express EphA2. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Andersen-Tawil Syndrome: Flecainide Therapy Study

We are exploring whether flecainide alone or in combination with other medications is more effective for managing heart rhythm issues in patients with Andersen-Tawil syndrome and multifocal ectopic contractions.

Andersen-Tawil SyndromeMultifocal Ectopic Purkinje-related Premature Contractions≤3 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiology

Ulcerative Colitis: CICR-NAM Treatment Study

We are testing a new oral medication for people with mild to moderately active ulcerative colitis. The goal is to see if it helps improve symptoms and overall gut health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementGastroenterology

Vitamin D3 Doses in Critically Ill Patients on Kidney Support

We are comparing two doses of vitamin D3 to see how they affect vitamin levels and health outcomes in ICU patients receiving kidney support. This study may help improve treatment for those with severe vitamin D deficiency.

Vitamin D DeficiencyMonitoring phase (IV)6-10 visitsNo PlaceboInvestigational MedicinesEndocrinologyNephrology

Tezepelumab for Progressive Pulmonary Fibrosis

We are studying whether Tezepelumab can help reduce symptoms and improve lung function in people with progressive pulmonary fibrosis and high eosinophil levels. This trial compares the medication to a placebo to evaluate its effectiveness.

Interstitial Pulmonary Fibrosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemotePulmonology

Cirrhosis Treatment: Efinopegdutide Study

We are testing efinopegdutide in adults with compensated cirrhosis caused by metabolic dysfunction. The study aims to see if it can reduce liver fat and improve liver health compared to a placebo.

Non-alcoholic Steatohepatitis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesEndocrinologyHepatology

Regorafenib for Recurrent Grade 2 and 3 Meningioma

We are studying whether Regorafenib can help patients with recurrent grade 2 and 3 meningiomas live longer without disease progression after surgery and radiotherapy. The trial also looks at overall survival, quality of life, and potential side effects.

Malignant Meningioma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Cognitive Impairment in Parkinson's: Donepezil Study

We are studying whether donepezil can improve cognitive function in people with mild cognitive impairment due to Parkinson's disease. The trial will also evaluate its effects on mental health and quality of life.

Parkinson's Disease6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesNeurology

Takotsubo Syndrome: Cyclosporine A Treatment Study

We are investigating whether cyclosporine A can help reduce heart damage in patients with Takotsubo syndrome compared to a placebo. This study aims to improve treatment options for this heart condition.

Healthy Participants>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesCardiologyInternal Medicine

Ribociclib for Cancer Patients: Continued Access Study

We are offering patients who previously benefited from ribociclib the chance to continue treatment. This study also aims to collect important safety information about ribociclib alone or with other investigational therapies.

Advanced CancerSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Non-Small Cell Lung Cancer: Immunotherapy and Chemotherapy Study

We are studying a treatment combining immunotherapy, chemotherapy, and radiotherapy for patients with newly diagnosed non-small cell lung cancer that has spread to a few other areas. The aim is to see if this approach helps patients live longer without their cancer worsening.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Myotonic Dystrophy: Long-Term Study of Mexiletine PR

We are examining the long-term safety and effectiveness of mexiletine PR for treating myotonia in patients with myotonic dystrophy types 1 and 2. This study is for those who have completed a prior related study.

Myotonic Dystrophy1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Parkinson’s Disease and Multiple System Atrophy: Exidavnemab Study

We are testing the safety and tolerability of a new treatment called exidavnemab in patients with Parkinson’s disease and Multiple System Atrophy. This study will help us understand how well different doses are accepted by patients.

Parkinson's DiseaseMultiple System Atrophy6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteNeurology

THEO-260 for Ovarian Cancer Treatment

We are studying a new treatment for patients with high-grade serous or endometrioid ovarian cancer to see if it is safe and effective. This trial will help us understand the best dose and how well it works compared to existing options.

Ovarian Cancer>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Glioblastoma: Meclofenamate with Temozolomide

We are studying whether adding meclofenamate to standard temozolomide therapy helps patients with progressive MGMT-methylated glioblastoma. The trial will assess safety, effectiveness, and quality of life improvements.

Glioblastoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Blood Cancer: Long-term Study of Zanubrutinib

We are evaluating the long-term safety and effectiveness of Zanubrutinib in patients with B-cell malignancies. This study is for those who have previously participated in a related trial.

B-cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology